Using MR-C as a screening tool at baseline in those patients with NSCLC without driver mutations/ALK translocation, who are eligible for ICI, makes it possible to identify BM early on in the ICI treatment course with the potential of offering an individualized treatment strategy. The gene discussed is ALK; the disease is non-small cell lung carcinoma.